DEF 14A: Xilio Therapeutics Seeks Stockholder Approval for Option Repricing, New Equity Plan

Xilio Therapeutics will hold a special meeting on November 21, 2025, to vote on repricing underwater employee stock options and approving a new 2025 Stock Incentive Plan to address significant dilution and retain talent.

Summary

• A special meeting of stockholders is scheduled for November 21, 2025, to vote on three key proposals.
• Proposal 1 seeks approval for a one-time repricing of certain outstanding employee stock options granted before January 1, 2025, which are currently "underwater" (exercise price higher than market price).
• As of September 30, 2025, approximately 87% of outstanding employee stock options were underwater, with exercise prices ranging from $0.858 to $16.00 per share, compared to a closing price of $0.843 per share.
• The repricing would set new exercise prices at $1.50 per share for the executive team and $1.00 per share for other employees (or the closing price on the repricing date if higher), with the benefit of the new price taking effect 12 months after approval.
• Proposal 2 requests approval for the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan, reserving 32.0 million shares for new stock option grants to employees.
• This new plan is designed to counteract significant dilution from 25.6 million prefunded warrants issued in 2024 and 266.7 million warrants issued in June 2025.
• The 2025 Plan's 32.0 million shares are divided into four equal tranches, with vesting for three tranches tied to the exercise or cancellation of the June 2025 common stock warrants, aligning employee incentives with capital inflow.
• The company's current equity overhang (shares underlying awards + shares available for future grants as a percentage of outstanding shares) was 27.0% as of September 30, 2025, but would drop to 4.1% assuming full exercise of all outstanding warrants, which is significantly below peer group averages.
• With the 2025 Plan, the overhang would be approximately 13.4% after full warrant exercise, still below the 25th percentile of peer companies.
• Proposal 3 is a standard request to approve an adjournment of the special meeting if necessary to solicit additional proxies.

Sentiment

Score: 6

Explanation: The filing addresses critical issues of employee motivation and retention in a challenging market, which is a positive step for operational stability. However, it also highlights significant past dilution and a substantial decline in stock price, indicating underlying difficulties. The proposals are corrective actions rather than indicators of strong growth, hence a neutral-positive score.

Positives

• Repricing underwater stock options aims to restore employee motivation and retention, which is critical for achieving drug discovery and development goals.
• The 2025 Stock Incentive Plan directly addresses significant dilution from recent warrant issuances, helping to maintain competitive equity compensation.
• The new plan's vesting conditions for Tranches 2, 3, and 4 are tied to the exercise or cancellation of common stock warrants, aligning employee interests with long-term stockholder value and potential capital inflow.
• Exclusion of non-employee directors from both the repricing and the 2025 Plan demonstrates a focus on employee incentives.
• The 2025 Plan incorporates strong corporate governance features, including no evergreen provision, a clawback policy, double-trigger acceleration on change in control, and no liberal share recycling.
• The repricing includes a 12-month retention period for employees to benefit from the new exercise price, encouraging continued service.

Negatives

• The stock option repricing and the new 2025 Stock Incentive Plan will result in further dilution for existing stockholders, even if structured to align interests.
• The company's stock price has significantly declined from $16.00 at IPO in October 2021 to $0.843 on September 30, 2025, indicating substantial value erosion.
• A large percentage (87%) of employee stock options being underwater for an extended period highlights past performance challenges and potential employee dissatisfaction.
• The need for these proposals indicates a struggle to retain talent and maintain competitive compensation in a challenging biotechnology market.
• The overhang, even with the new plan, remains below the 25th percentile of peers, suggesting the company may still face challenges in offering highly competitive equity incentives.
• The repricing of options for executives at a higher new exercise price ($1.50 vs. $1.00 for other employees) could be perceived negatively by some non-executive employees or external stakeholders.

Risks

• Failure to approve the option repricing and/or the 2025 Stock Incentive Plan could severely impact the company's ability to motivate, incentivize, and retain qualified employees, exacerbating retention concerns in a highly competitive market.
• If the 2025 Plan is not approved, the company may be forced to increase cash compensation, reducing resources available for business needs and objectives.
• The significant dilution from the 2024 prefunded warrants and June 2025 warrants (totaling 292.3 million warrants outstanding) presents ongoing challenges to equity compensation effectiveness.
• The biotechnology industry faces inherent challenges in the research and development of novel product candidates for immuno-oncology, contributing to stock price volatility and investor sentiment pressures.
• The accounting impact of the repricing will result in recognition of incremental compensation expense.
• The repricing may convert some incentive stock options to nonstatutory stock options for tax purposes, and restart holding periods, which could have tax implications for employees.

Future Outlook

The company believes it is well-positioned to achieve its business objectives and advance its pipeline of tumor-activated immuno-oncology molecules. Approval of the proposals is considered vital for future success, enabling the company to motivate, incentivize, and retain employees and conserve cash resources for development and growth.

Management Comments

• Our board of directors believes it is in the best interests of stockholders to motivate, incentivize and retain our employees.
• We believe we are well-positioned to achieve our business objectives, but the significant dilution from these warrants presents challenges to our ability to motivate, incentivize and retain qualified employees through equity awards.
• Our board of directors believes that the underwater stock options are not effective in motivating, incentivizing and retaining employees, which our board of directors believes are important for long-term stockholder value.
• We believe this combined approach reflects the best way to achieve our related goals of providing meaningful equity incentives to motivate, incentivize and retain our valued employees and building long-term stockholder value.
• Our board of directors urges stockholders to approve the stock option repricing as our board of directors believes that implementing it is critical to our success.
• If our employees do not have certainty that their equity holdings (which are already significantly below market) will be protected from the dilution resulting from these warrants, our already significant retention concerns will be exacerbated in what is a highly competitive market.

Industry Context

The biotechnology industry has experienced significant challenges since Xilio's initial public offering in 2021, leading to a decline in market value and worsening investor sentiment, particularly within immuno-oncology. The company faces intense competition for experienced and talented employees with critical and high-demand skills in this sector.

Comparison to Industry Standards

• The company's equity overhang, even after accounting for the proposed 2025 Plan and full warrant exercise, would be approximately 13.4%, which is still below the 25th percentile of its peer group and other companies it competes with for talent.
• The company's equity compensation program is stated to be consistent with the compensation philosophy and practices of other pharmaceutical companies in its peer group and other companies it competes with for talent, despite the current challenges.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from repriced options and new equity grants, but the proposals aim to align employee incentives with long-term stockholder value and ensure retention of critical talent, which is vital for the company's strategic objectives and pipeline advancement. The vesting of new options tied to warrant exercise could lead to capital inflow.
• Employees: Will benefit from restored equity value through repriced options and new stock option grants, addressing the issue of significantly underwater options and dilution from recent warrant issuances, thereby enhancing motivation and retention in a competitive labor market.
• Company Operations: Improved ability to attract, motivate, and retain key personnel, which is crucial for achieving drug discovery and development goals and advancing the immuno-oncology pipeline. The proposals also aim to conserve cash resources by relying on equity compensation.

Next Steps

• Stockholders will vote on the option repricing, the 2025 Stock Incentive Plan, and an adjournment proposal at the special meeting on November 21, 2025.
• If approved, the stock option repricing will be implemented automatically following the close of trading on the date of the special meeting.
• If the 2025 Plan is approved, the company intends to register the additional shares reserved for issuance by filing a Registration Statement on Form S-8 as soon as practicable.
• If the 2025 Plan is not approved, the contingent stock options will be automatically cancelled, and the board will consider alternative arrangements.
• The company plans to announce preliminary voting results at the special meeting and report final results in a Current Report on Form 8-K within four business days.
• The 2021 Plan will continue to be used for promotion and retention grants to employees, and grants to non-employee directors, consultants, and advisors, with annual equity awards for employees expected to resume in 2027.
• The Inducement Plan will continue to be used for inducement grants to newly hired employees.

Key Dates

Recommendation

The proposals address critical issues of employee motivation and retention following significant stock price decline and dilution from recent warrant issuances. While the repricing and new equity plan introduce further dilution, they are presented as necessary corrective actions to stabilize the workforce and align employee incentives with long-term company performance. For a seasoned investor, these actions are essential for the company's operational continuity and ability to execute its strategic pipeline. The unanimous board recommendation and the inclusion of corporate governance safeguards in the new plan suggest a considered approach to mitigating negative impacts. The company operates in a challenging biotech environment, and these measures are about maintaining viability and future potential rather than signaling immediate strong growth, thus a 'hold' recommendation is appropriate, pending further operational and financial performance.

Keywords

Xilio Therapeutics, Stock Options, Equity Compensation, Option Repricing, Stock Incentive Plan, Employee Retention, Dilution, Warrants, Biotechnology, Immuno-Oncology, Corporate Governance, SEC Filing, Proxy Statement